E-Book Overview
Pharmaceutical costs are among the fastest growing components of health care costs today. Although increases in the inflation-adjusted prices of ethical drugs and perceived high prices of new drugs have been a concern of congressional committees for over 30 years, the growing Federal role in paying for prescription drugs has increased the concern over the appropriateness of prices relative to the costs of bringing new drugs to market. Specific policies of U.S. and other governments can alter the delicate balance between costs and returns to pharmaceutical R&D. with ramifications for the future health of Americans, for health care costs, and for the future of the U.S. pharmaceutical industry.OTA's report focuses mainly on the economic side of the R&D process. Pharmaceutical R&D is an investment, and the principal characteristic of an investment is that money is spent today in the hopes of generating even more money in the future. Pharmaceutical R&D is a risky investment: therefore, high financial returns are necessary to induce companies to invest in researching new chemical entities. Changes in Federal policy that affect the cost, uncertainty and returns of pharmaceutical R&D may have dramatic effects on the investment patterns of the industry. Given this sensitivity to policy changes, careful consideration of the effects on R&D is needed.
E-Book Content
Pharmaceutical R&D: Costs, Risks, and Rewards February 1993 OTA-H-522 NTIS order #PB93-163376 GPO stock #052-003-01315-1 Huangzhiman 2003.12.30 www.dnathink.org Recommended Citation: U.S. Congress, Office of Technology Assessment, PhurrnaceuficaZ R&D: Costs, Ris/u and Rewards, OTA-H-522 (Washington, DC: U.S. Government Printing Office, February 1993). Supt. I [:or ,L,lc ~, I]W 11. s. (;()~cnln]cn[ Pnntlng OI!ICC IIIIL.IIdCI)[ (II [)ocumcnl.. ?Iiill Slop: SSOP. W.i.hlngl(m, 1)(’ ?(M()? ISB